A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes

Background: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded to guide rational use of EGFR-targeted therapies.

Bibliographic Details

Published in:	Cellular Oncology
Main Authors:	D. A. M. Heideman, F. B. Thunnissen, M. Doeleman, D. Kramer, H. M. Verheul, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, G.A. Meijer, P. J. F. Snijders
Format:	Article
Language:	English
Published:	Wiley 2009-01-01
Online Access:	http://dx.doi.org/10.3233/CLO-2009-0489